Research record
Overview
Compound name: Tirzepatide
Alternative names: Mounjaro (brand name for type 2 diabetes), Zepbound (brand name for weight management)
Compound classification: Synthetic peptide; dual receptor agonist
Brief factual description:
Tirzepatide is a synthetic peptide therapeutic designed as a dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist. It is used clinically to improve glycemic control in adults with type 2 diabetes and for chronic weight management in adults with obesity or overweight with related conditions.
Mechanism of Action
Primary biological targets:
GIP receptors (GIPR)
GLP-1 receptors (GLP-1R)
Affected systems: Endocrine, metabolic, gastrointestinal
Receptor selectivity: Dual agonist activity enhances incretin effects beyond traditional GLP-1R agonists
Downstream signaling effects:
Increased glucose-dependent insulin secretion
Reduced inappropriate glucagon secretion
Delayed gastric emptying and enhanced satiety signaling
